<DOC>
	<DOCNO>NCT00480181</DOCNO>
	<brief_summary>The purpose study determine whether nabilone ( Cesamet ) use adjunctive agent gabapentin ( Neurontin ) provide significantly improve pain relief gabapentin alone management neuropathic pain MS .</brief_summary>
	<brief_title>Efficacy Safety Evaluation Nabilone Adjunctive Therapy Gabapentin Management Neuropathic Pain Multiple Sclerosis</brief_title>
	<detailed_description>Neuropathic pain syndrome , occur due damage central and/or peripheral nerve axon , often difficult manage commonly refractory conventional analgesia approach describe World Health Organization , include NSAIDs narcotic agent . These pain syndrome often describe symptom burn , stab , crawl , shock-like , numbness and/or tingling , quite concern patient , especially inadequate response treatment . It estimate prevalence chronic pain MS range anywhere 30-90 % , place second bad disease-induced symptom experience patient population . The pathophysiologic cause pain syndrome complex multifaceted , one specific link attribute pain response . Due complexity neuropathic pain - partially understood best - may necessary many case treat source pain one agent order address many different contributor pain process . More thorough review currently available agent NPP work together would provide clinician safety efficacy data would aid provide optimal pain management .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Nabilone</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>Males female age 1865 year old clinically definite RRMS EDSS &lt; 6.5 Current treatment gabapentin effective stabilize dose ( &gt; 1800mg/day ) least 1 month . Visual Analogue Scale score NPP symptom &gt; 5 ; pain present least 3 month Negative serum pregnancy test female childbearing age ; currently breastfeed No history alcohol substance abuse No history nonpsychotic emotional disorder No significant hepatic renal insufficiency No significant cardiovascular disease hypertension No know hypersensitivity and/or allergy nabilone derivatives No current use cannabinoid relate product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Neuropathic pain</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Nabilone</keyword>
	<keyword>Gabapentin</keyword>
</DOC>